Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's Largest Kampo Drug Maker Tsumura Sells Subsidiary

This article was originally published in PharmAsia News

Executive Summary

Japan's largest Kampo - the Japanese adaptation of traditional Chinese medicine - maker Tsumura announced July 15 that it will sell its wholly owned subsidiary Tsumura Lifescience to Wise Partners, a fund that has invested in the subsidiary. The total amount involved is ¥4.55 billion. In fiscal year 2007, Tsumura Life Science had profits of ¥300 million on ¥12.3 billion in sales. Tsumura plans to further focus on its core area, manufacturing and marketing kampo, which accounts for over 80 percent of the company's sales. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts